Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
emtricitabine + darunavir + cobicistat + maraviroc
- Development stage
- Phase 4
- Lead developer
- Johnson & Johnson
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This specific combination of emtricitabine, darunavir, cobicistat, and maraviroc does not appear to be a standard or FDA-approved combination drug based on available information. The closest similar combination is Symtuza, which contains darunavir, cobicistat, emtricitabine, and tenofovir alafenamide (not maraviroc).
02
Targets
CCR5 (C-C chemokine receptor type 5)CYP3A4 (Cytochrome P450 3A4)PR (Progesterone receptor)Human immunodeficiency virus type 1 reverse transcriptase
Beyond the preview
Go deeper on emtricitabine + darunavir + cobicistat + maraviroc.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on emtricitabine + darunavir + cobicistat + maraviroc.